Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Proteogenomics Study of Lung Cancer

ABSTRACT: Lung cancer remains the leading cause of cancer-related mortality worldwide, with limited treatment options for advanced stages. This proteogenomics study aims to integrate multi-omics approaches, including proteomics, genomics, and transcriptomics, to elucidate the molecular mechanisms underlying lung cancer progression and treatment resistance. By leveraging cutting-edge technologies, this study seeks to identify novel biomarkers and therapeutic targets, enabling personalized medicine strategies to improve patient outcomes. The integration of proteogenomic data will provide a comprehensive understanding of tumor biology, revealing critical pathways and interactions that drive tumorigenesis and immune evasion.

ORGANISM(S): Homo sapiens

PROVIDER: GSE283245 | GEO | 2024/12/02

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy [WES]

Project description:Therapeutic approaches to treat melanoma include small molecule drugs that target activating protein mutations in pro-growth signaling pathways like the MAPK pathway. While beneficial to the approximately 50% of patients with activating BRAFV600 mutation, mono- and combination therapy with MAPK inhibitors is ultimately associated with acquired resistance. To better characterize the mechanisms of MAPK inhibitor resistance in melanoma, we utilize patient-derived xenografts and apply proteogenomic approaches leveraging genomic, transcriptomic, and proteomic technologies that permit the identification of resistance-specific alterations and therapeutic vulnerabilities. A specific challenge for proteogenomic applications comes at the level of data curation to enable multi-omics data integration. Here, we present a proteogenomic approach that uses custom curated databases to identify unique resistance-specific alternations in melanoma PDX models of acquired MAPK inhibitor resistance. We demonstrate this approach with a NRASQ61L melanoma PDX model from which resistant tumors were developed following treatment with a MEK inhibitor. Our multi-omics strategy addresses current challenges in bioinformatics by leveraging development of custom curated proteogenomics databases derived from individual resistant melanoma that evolves following MEK inhibitor treatment and is scalable to comprehensively characterize acquired MAPK inhibitor resistance across patient-specific models and genomic subtypes of melanoma.

2024-05-10 | GSE266735 | GEO

Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy [RNA-seq]

2024-05-10 | GSE266762 | GEO

Proteogenomics Study of Lung Cancer

Project description:Proteogenomics Study of Lung Cancer

| PRJNA1192953 | ENA

International Cancer Proteogenomics Consortium (ICPC): Proteogenomics of East-Asian Breast Cancer

Project description:International Cancer Proteogenomics Consortium (ICPC): Proteogenomics of East-Asian Breast Cancer

| PRJNA909917 | ENA

International Cancer Proteogenomics Consortium (ICPC): Proteogenomics of East-Asian Breast Cancer

Project description:International Cancer Proteogenomics Consortium (ICPC): Proteogenomics of East-Asian Breast Cancer

| PRJNA909918 | ENA

Prokaryotic Proteogenomics

Project description:Prokaryotic Proteogenomics

| PRJNA66995 | ENA

Individualized proteogenomics reveals mutational landscape of melanoma patients in response to immunotherapy

Project description:Immune checkpoint inhibitors are used to restore or augment antitumor immune response and show great promise in treatment of melanoma and other types of cancers. However, only a relatively small percentage of patients are fully responsive to immune checkpoint inhibition, mostly due to tumor heterogeneity and primary resistance to therapy. Both of these features are largely driven by accumulation of patient-specific mutations, pointing to the need for personalized approaches in diagnostics and immunotherapy. Proteogenomics integrates patient-specific genomic and proteomic data to study cancer development and resistance mechanisms, as well as tumor heterogeneity in individual patients. Here, we use a proteogenomic approach to characterize the mutational landscape of samples derived from four clinical melanoma patients at the genomic, proteomic and phosphoproteomic level. Integration of datasets enabled identification and quantification of an extensive number of sample-specific amino acid variants, among them many were not previously reported in melanoma. We detected a disproportional number of alternate peptides between treated and untreated (naïve) samples with a high potential to influence signal transduction. This is one of the first proteogenomic study designed to study the mutational landscape of patient-derived melanoma tissue samples in response to immunotherapy.

2022-02-16 | PXD028700 | Pride

Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy

2024-01-24 | MSV000093912 | MassIVE

LC-MSMS of primary AML class I immunopeptidome (ERE-derived MAPs identification approach)

Project description:The development of therapeutic anticancer vaccines calls for the identification of tumor-specific antigens (TSAs). Though a combination of four cutting-edge proteogenomic approaches, we performed a deep exploration of the MHC-I presented peptides (MAPs) of 19 acute myeloid leukemia (AML) patients and identified various TSAs that could serve for the design of an anti-AML vaccine.

2021-03-19 | PXD018542 | Pride

LC-MSMS of primary AML class I immunopeptidome (Canonical personalized proteome)

2021-03-19 | PXD018541 | Pride